InspireMD Beheer

Beheer criteriumcontroles 1/4

De CEO InspireMD is Marvin Slosman, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.22M, bestaande uit 14.6% salaris en 85.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde $ 16.94K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 8.2 jaar.

Belangrijke informatie

Marvin Slosman

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris	14.6%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Jan 11

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

Feb 11

Analyse CEO-vergoeding

Hoe is Marvin Slosman's beloning veranderd ten opzichte van InspireMD's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$3m	US$470k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$697k	US$433k	-US$18m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$410k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$367k	-US$11m

Compensatie versus markt: De totale vergoeding ($USD 3.22M ) Marvin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Marvin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Marvin Slosman (60 yo)

4.8yrs

Tenure

US$3,219,321

Compensatie

Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% $ 16.9k
Craig Shore	CFO, Chief Administrative Officer	1.1yrs	US$1.80m	9.2% $ 6.4m
Shane Gleason	Chief Commercial Officer	1.3yrs	US$1.15m	2.08% $ 1.4m
Andrea Tommasoli	Chief Operating Officer	1.7yrs	US$359.27k	1.94% $ 1.3m
Amir Kohen	Senior Vice President of Finance & HR	1.1yrs	geen gegevens	geen gegevens
Patrick Verta	Executive Vice President of Clinical & Medical Affairs	1.1yrs	geen gegevens	0.71% $ 493.8k
Pete Ligotti	Executive VP & GM of North America	less than a year	geen gegevens	geen gegevens
Sol Barer	Special Advisor to the Board	no data	US$13.92k	geen gegevens

1.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NSPR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% $ 16.9k
Michael Berman	Independent Director	11.8yrs	US$380.25k	1.59% $ 1.1m
Elazer Edelman	Member of Advisory Board	no data	geen gegevens	geen gegevens
Thomas Kester	Independent Director	8.2yrs	US$385.25k	1.25% $ 865.6k
Antonio Colombo	Member of Advisory Board	no data	geen gegevens	geen gegevens
Alexandre Abizaid	Member of Advisory Board	no data	geen gegevens	geen gegevens
Martin B. Leon	Member of Advisory Board	no data	geen gegevens	geen gegevens
Eberhart Grube	Member of Advisory Board	no data	geen gegevens	geen gegevens
Paul Stuka	Independent Chairman of the Board	13.3yrs	US$574.93k	1.19% $ 825.6k
Kenneth Rosenfield	Chair of Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Yaron Almagor	Member of Advisory Board	no data	geen gegevens	geen gegevens
Edo Kaluski	Member of Advisory Board	no data	geen gegevens	geen gegevens

8.2yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NSPR wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

InspireMD Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Independent Director exercised options to buy US$153k worth of stock.

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Insider recently bought US$127k worth of stock

InspireMD, Inc. Announces Management Appointments

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024

InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director exercised options to buy US$153k worth of stock.

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Insider recently bought US$127k worth of stock

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

Consensus estimates of losses per share improve by 46%

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus revenue estimates decrease by 37%, EPS upgraded

Price target decreased to US$5.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought US$68k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$9.00

Full year 2021 earnings: EPS misses analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully

Insider recently bought US$50k worth of stock

Insider recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

InspireMD: Revolutionizing The Field Of Vascular Stenting

Insider recently bought US$93k worth of stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Earnings beat expectations, revenue disappoints

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: US$0.82

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: US$0.71

New 90-day high: US$0.44

Analysts update estimates